Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
Brilinta
Generic name / active ingredient
ticagrelor
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-23

Copy from the pack in hand

Source-linked reading points

  • Check BRILINTA, ticagrelor, 60 mg or 90 mg, NDC, 60-tablet bottle and target market together. mg is the labelled amount per tablet; the same brand, a similar colour or being described as clot prevention does not make another tablet, pack or market product self-convertible.
  • The label involves professional judgement around bleeding risk, aspirin, other antiplatelet/anticoagulant products, surgery or dental procedures and multiple interactions. Do not change the amount, frequency, combination, pause or restart of any product based only on packs at home, online anecdotes or one symptom.
  • This exact U.S. label contains product-specific wording for handling certain tablets; it is not permission for anyone to self-split, crush, convert or change amounts for any pack, market or other tablet. With handling difficulty, a medicine transition or uncertainty about use, have a pharmacist or prescribing team review the actual pack and complete medicine list.
  • With significant or unexplained bleeding, black stools, coughing/vomiting blood, head injury, sudden chest pain, breathing trouble or neurological symptoms, use local urgent and medical pathways; do not infer continuation, pause or make-up use from this page.

Reviewed presentation examples — compare every field

  • 60 mg per tablet; 60-tablet bottleNDC 0186-0776-60
  • 90 mg per tablet; 60-tablet bottleNDC 0186-0777-60

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-23
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image